CN101636399B - 可用作plk1抑制剂的取代的嘧啶并二氮杂* - Google Patents
可用作plk1抑制剂的取代的嘧啶并二氮杂* Download PDFInfo
- Publication number
- CN101636399B CN101636399B CN2008800088890A CN200880008889A CN101636399B CN 101636399 B CN101636399 B CN 101636399B CN 2008800088890 A CN2008800088890 A CN 2008800088890A CN 200880008889 A CN200880008889 A CN 200880008889A CN 101636399 B CN101636399 B CN 101636399B
- Authority
- CN
- China
- Prior art keywords
- methyl
- mol
- tetrahydro
- pyrimido
- diazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*c(cc1)c(*)cc1C(C)=C Chemical compound C*c(cc1)c(*)cc1C(C)=C 0.000 description 4
- YAVPDSQCYSZORP-UHFFFAOYSA-N CC(C)(CN)C(OC)=O Chemical compound CC(C)(CN)C(OC)=O YAVPDSQCYSZORP-UHFFFAOYSA-N 0.000 description 1
- YXFXMCIKLDSJQP-UHFFFAOYSA-N CC(C)(CNC1CCCC1)C(OC)=O Chemical compound CC(C)(CNC1CCCC1)C(OC)=O YXFXMCIKLDSJQP-UHFFFAOYSA-N 0.000 description 1
- UEUSVRKLHQLRPG-UHFFFAOYSA-N CC(C1N2C)N=C(Nc(ccc(C(NC3CCN(C)CC3)=O)c3)c3OC)N=C1N(C1CCCC1)C(CCC1)C1C2=O Chemical compound CC(C1N2C)N=C(Nc(ccc(C(NC3CCN(C)CC3)=O)c3)c3OC)N=C1N(C1CCCC1)C(CCC1)C1C2=O UEUSVRKLHQLRPG-UHFFFAOYSA-N 0.000 description 1
- IBPQWZCJXXORJW-UHFFFAOYSA-N CC(CCC1)C1N(CC1)c2nc(Nc(ccc(C(NC3CCN(C)CC3)=O)c3)c3OC)ncc2N(C)C1=O Chemical compound CC(CCC1)C1N(CC1)c2nc(Nc(ccc(C(NC3CCN(C)CC3)=O)c3)c3OC)ncc2N(C)C1=O IBPQWZCJXXORJW-UHFFFAOYSA-N 0.000 description 1
- NWFUUMOYXWJFAW-UHFFFAOYSA-N CC(CN(C1CCCC1)c1nc(Nc2cccc(C(NC3CCN(C)CC3)=O)c2)ncc1N1C)C1=O Chemical compound CC(CN(C1CCCC1)c1nc(Nc2cccc(C(NC3CCN(C)CC3)=O)c2)ncc1N1C)C1=O NWFUUMOYXWJFAW-UHFFFAOYSA-N 0.000 description 1
- PZZZXKULVIYCFD-UHFFFAOYSA-N CC(CN(C1CCCC1)c1nc(Nc2cccc(C(Nc3cccnc3)=O)c2)ncc1N1C)C1=O Chemical compound CC(CN(C1CCCC1)c1nc(Nc2cccc(C(Nc3cccnc3)=O)c2)ncc1N1C)C1=O PZZZXKULVIYCFD-UHFFFAOYSA-N 0.000 description 1
- NTAPIYCYAPUYAA-UHFFFAOYSA-N CCC(C)N(C(C)C1C)c2nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)ncc2N(C)C1=O Chemical compound CCC(C)N(C(C)C1C)c2nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)ncc2N(C)C1=O NTAPIYCYAPUYAA-UHFFFAOYSA-N 0.000 description 1
- XEKFRLOGRRTZHJ-UHFFFAOYSA-N CCCC(CC)N(CC1C)c2nc(Nc(c(C)c3)ccc3C(NC3CCN(CC)CC3)=O)ncc2N(C)C1=O Chemical compound CCCC(CC)N(CC1C)c2nc(Nc(c(C)c3)ccc3C(NC3CCN(CC)CC3)=O)ncc2N(C)C1=O XEKFRLOGRRTZHJ-UHFFFAOYSA-N 0.000 description 1
- QDYSTZCQVLKVMY-UHFFFAOYSA-O CN(c1c(N(CC2)C3CCC3)nc(Nc(ccc(C(N)=O)c3)c3OC)nc1)C2=[OH+] Chemical compound CN(c1c(N(CC2)C3CCC3)nc(Nc(ccc(C(N)=O)c3)c3OC)nc1)C2=[OH+] QDYSTZCQVLKVMY-UHFFFAOYSA-O 0.000 description 1
- UTBZTRCXJYYXPF-UHFFFAOYSA-N COc1c(CNc(nc2)nc(N(CC3)C4CCC4)c2NC3O)cccc1 Chemical compound COc1c(CNc(nc2)nc(N(CC3)C4CCC4)c2NC3O)cccc1 UTBZTRCXJYYXPF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91935807P | 2007-03-22 | 2007-03-22 | |
| US60/919,358 | 2007-03-22 | ||
| PCT/EP2008/052847 WO2008113711A1 (en) | 2007-03-22 | 2008-03-11 | Substituted pyrimidodiazepines useful as plk1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210030872.3A Division CN102746175B (zh) | 2007-03-22 | 2008-03-11 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101636399A CN101636399A (zh) | 2010-01-27 |
| CN101636399B true CN101636399B (zh) | 2012-04-18 |
Family
ID=39415299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800088890A Expired - Fee Related CN101636399B (zh) | 2007-03-22 | 2008-03-11 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
| CN201210030872.3A Expired - Fee Related CN102746175B (zh) | 2007-03-22 | 2008-03-11 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210030872.3A Expired - Fee Related CN102746175B (zh) | 2007-03-22 | 2008-03-11 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
Country Status (23)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008287339A1 (en) | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| BRPI0817315A2 (pt) * | 2007-09-25 | 2015-03-17 | Takeda Pharmaceutical | Inibidores de quinase do tipo polo |
| CN101878216B (zh) * | 2007-09-28 | 2013-07-10 | 西克拉塞尔有限公司 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
| WO2009153197A1 (en) * | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| EP2379559B1 (en) | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| WO2011031965A1 (en) | 2009-09-14 | 2011-03-17 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP2970317A4 (en) | 2013-03-15 | 2016-11-02 | Dana Farber Cancer Inst Inc | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| PT3068776T (pt) | 2013-11-13 | 2019-08-26 | Vertex Pharma | Inibidores da replicação de vírus da gripe |
| HUE038820T2 (hu) | 2013-11-13 | 2018-11-28 | Vertex Pharma | Eljárás influenzavírusok replikációjának inhibitorai elõállítására |
| EP3099693A4 (en) * | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| CN107074860B (zh) | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| AU2017248186B2 (en) * | 2016-04-07 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020356484A1 (en) | 2019-09-27 | 2022-03-17 | Dana-Farber Cancer Institute, Inc. | ERK5 degraders as therapeutics in cancer and inflammatory diseases |
| US20230158158A1 (en) * | 2020-03-27 | 2023-05-25 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| JP7555155B2 (ja) * | 2021-08-10 | 2024-09-24 | オップテラ インコーポレイテッド | 新規plk1分解誘導化合物 |
| GB202313514D0 (en) | 2023-09-05 | 2023-10-18 | Cambridge Entpr Ltd | Treatment of inflammatory diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390220A (zh) * | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的激酶抑制剂 |
| CN1551881A (zh) * | 2001-09-04 | 2004-12-01 | ���ָ��Ӣ��ķ�������Ϲ�˾ | 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE479434T1 (de) * | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
-
2008
- 2008-03-11 CN CN2008800088890A patent/CN101636399B/zh not_active Expired - Fee Related
- 2008-03-11 DK DK08717594.9T patent/DK2139892T3/da active
- 2008-03-11 WO PCT/EP2008/052847 patent/WO2008113711A1/en not_active Ceased
- 2008-03-11 CA CA002680757A patent/CA2680757A1/en not_active Abandoned
- 2008-03-11 AT AT08717594T patent/ATE524472T1/de active
- 2008-03-11 KR KR1020097019761A patent/KR101157848B1/ko not_active Expired - Fee Related
- 2008-03-11 HR HR20110807T patent/HRP20110807T1/hr unknown
- 2008-03-11 EP EP08717594A patent/EP2139892B1/en not_active Not-in-force
- 2008-03-11 MX MX2009010034A patent/MX2009010034A/es active IP Right Grant
- 2008-03-11 PT PT08717594T patent/PT2139892E/pt unknown
- 2008-03-11 ES ES08717594T patent/ES2371832T3/es active Active
- 2008-03-11 PL PL08717594T patent/PL2139892T3/pl unknown
- 2008-03-11 SI SI200830445T patent/SI2139892T1/sl unknown
- 2008-03-11 CN CN201210030872.3A patent/CN102746175B/zh not_active Expired - Fee Related
- 2008-03-11 BR BRPI0809088-2A patent/BRPI0809088A2/pt not_active IP Right Cessation
- 2008-03-11 JP JP2009553997A patent/JP5087640B2/ja not_active Expired - Fee Related
- 2008-03-11 AU AU2008228303A patent/AU2008228303B2/en not_active Ceased
- 2008-03-18 CL CL2008000785A patent/CL2008000785A1/es unknown
- 2008-03-19 PE PE2011001933A patent/PE20120495A1/es not_active Application Discontinuation
- 2008-03-19 TW TW097109660A patent/TWI363629B/zh not_active IP Right Cessation
- 2008-03-19 AR ARP080101142A patent/AR065794A1/es unknown
- 2008-03-19 US US12/051,000 patent/US7517873B2/en not_active Expired - Fee Related
-
2009
- 2009-08-27 IL IL200617A patent/IL200617A/en not_active IP Right Cessation
-
2011
- 2011-11-30 CY CY20111101174T patent/CY1112102T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390220A (zh) * | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的激酶抑制剂 |
| CN1551881A (zh) * | 2001-09-04 | 2004-12-01 | ���ָ��Ӣ��ķ�������Ϲ�˾ | 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102746175A (zh) | 2012-10-24 |
| AR065794A1 (es) | 2009-07-01 |
| HK1139936A1 (en) | 2010-09-30 |
| IL200617A (en) | 2014-02-27 |
| US7517873B2 (en) | 2009-04-14 |
| CL2008000785A1 (es) | 2009-03-27 |
| CA2680757A1 (en) | 2008-09-25 |
| AU2008228303B2 (en) | 2012-04-19 |
| TW200843781A (en) | 2008-11-16 |
| KR101157848B1 (ko) | 2012-07-11 |
| MX2009010034A (es) | 2009-10-12 |
| EP2139892A1 (en) | 2010-01-06 |
| HRP20110807T1 (hr) | 2011-12-31 |
| PE20120495A1 (es) | 2012-05-12 |
| PL2139892T3 (pl) | 2012-03-30 |
| BRPI0809088A2 (pt) | 2014-09-09 |
| TWI363629B (en) | 2012-05-11 |
| ATE524472T1 (de) | 2011-09-15 |
| EP2139892B1 (en) | 2011-09-14 |
| JP5087640B2 (ja) | 2012-12-05 |
| WO2008113711A1 (en) | 2008-09-25 |
| AU2008228303A1 (en) | 2008-09-25 |
| PT2139892E (pt) | 2011-11-21 |
| CN101636399A (zh) | 2010-01-27 |
| JP2010521514A (ja) | 2010-06-24 |
| KR20090119913A (ko) | 2009-11-20 |
| US20080234255A1 (en) | 2008-09-25 |
| SI2139892T1 (sl) | 2011-12-30 |
| CN102746175B (zh) | 2014-01-15 |
| DK2139892T3 (da) | 2011-12-12 |
| CY1112102T1 (el) | 2015-11-04 |
| IL200617A0 (en) | 2010-05-17 |
| ES2371832T3 (es) | 2012-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102746175B (zh) | 可用作plk1抑制剂的取代的嘧啶并二氮杂* | |
| CN108697714B (zh) | 稠合嘧啶化合物或其盐 | |
| CN104854101B (zh) | Alk激酶抑制剂 | |
| RU2671494C2 (ru) | Некоторые ингибиторы протеинкиназы | |
| WO2020207260A1 (zh) | 一种cdk激酶抑制剂及其应用 | |
| CN105121443B (zh) | 蛋白激酶抑制剂 | |
| CN113874015B (zh) | Ripk2的噻吩并吡啶抑制剂 | |
| CN107580597A (zh) | Pi3k抑制剂的盐及其制备方法 | |
| EP3768272B1 (en) | Jak inhibitors | |
| KR20220006104A (ko) | 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용 | |
| WO2019011228A1 (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| WO2022242697A1 (zh) | Tyk2选择性抑制剂及其用途 | |
| WO2022160931A1 (zh) | 吡啶并嘧啶类衍生物及其制备方法和用途 | |
| AU2021410926A9 (en) | Tetrahydrothienopyrimidinesulfonamide compounds | |
| KR20210131372A (ko) | Syk 억제제로서의 축합된 피라진의 고체 형태 | |
| CN114981270B (zh) | Mll1抑制剂和抗癌剂 | |
| CN110914273B (zh) | 用于治疗糖尿病的作为pde1抑制剂的[1,2,4]三唑并衍生物 | |
| CN115650974B (zh) | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用 | |
| WO2024240256A1 (zh) | 作为激酶抑制剂的多环化合物及其制备方法和用途 | |
| WO2026052129A1 (zh) | 多环杂芳烃类glp-1受体激动剂 | |
| KR20260025059A (ko) | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 | |
| HK40003732B (en) | Inhibitors of activin receptor-like kinase | |
| HK1240216B (en) | Certain protein kinase inhibitors | |
| BR112017018312B1 (pt) | Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED. Free format text: FORMER OWNER: HOFFMAN-LALUOAI CO., LTD. Effective date: 20100629 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: BASEL, SWITZERLAND TO: OSAKA, JAPAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100629 Address after: Osaka Applicant after: Takeda Chemical Industries, Ltd. Address before: Basel Applicant before: F. Hoffmann-La Roche AG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120418 Termination date: 20150311 |
|
| EXPY | Termination of patent right or utility model |